Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 570,119 | 642,951 | 748,953 | 540,599 | 681,101 |
| Marketable Securities | 17,363 | 2,991 | 7,939 | N/A | N/A |
| Receivables | 139,444 | 116,518 | 76,868 | 115,265 | 4,722 |
| Inventories | 26,753 | 24,527 | 18,277 | 3,954 | N/A |
| TOTAL | $797,749 | $839,382 | $912,277 | $695,173 | $720,692 |
| Non-Current Assets | |||||
| PPE Net | 5,366 | 5,830 | 6,107 | 6,698 | 7,011 |
| Investments And Advances | 79,972 | 92,168 | 108,002 | 128,191 | 143,747 |
| Intangibles | 28,077 | 28,795 | 29,513 | 27,802 | 23,926 |
| Other Non-Current Assets | 24,861 | 32,075 | 24,291 | 23,774 | 23,962 |
| TOTAL | $138,276 | $158,868 | $167,913 | $186,465 | $198,646 |
| Total Assets | $936,025 | $998,250 | $1,080,190 | $881,638 | $919,338 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 36,228 | 18,702 | 26,134 | 27,525 | 9,618 |
| Accrued Expenses | 118,139 | 90,774 | 68,482 | 67,077 | 92,601 |
| Other current liabilities | 120,222 | 92,743 | 65,916 | 40,674 | 33,071 |
| TOTAL | $287,971 | $216,600 | $175,854 | $152,105 | $154,400 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,852,470 | 1,851,016 | 1,849,559 | 1,848,124 | 1,721,382 |
| Deferred Revenues | 7,190 | 9,087 | 10,540 | 11,620 | 14,604 |
| Other Non-Current Liabilities | 860,287 | 842,449 | 819,939 | 504,525 | 486,554 |
| TOTAL | $2,724,065 | $2,704,402 | $2,682,310 | $2,367,971 | $2,222,692 |
| Total Liabilities | $3,012,036 | $2,921,002 | $2,858,164 | $2,520,076 | $2,377,092 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 193,863 | 192,709 | 191,169 | 189,881 | 190,189 |
| Common Shares | 202 | 200 | 198 | 197 | 196 |
| Retained earnings | -3,821,194 | -3,628,331 | -3,445,588 | -3,263,685 | -3,096,263 |
| Other shareholders' equity | 10,335 | 10,044 | 9,611 | 9,681 | 10,158 |
| TOTAL | $-2,076,011 | $-1,922,752 | $-1,777,974 | $-1,638,438 | $-1,457,754 |
| Total Liabilities And Equity | $936,025 | $998,250 | $1,080,190 | $881,638 | $919,338 |